Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Legend/Janssen CAR-T Immunotherapy to Start US Trial in Myeloma

publication date: May 30, 2018

Legend Biotech of Nanjing, a GenScript Biotech subsidiary, reported FDA approval of a US Phase Ib/II trial for its CAR-T therapy in patients with relapsed or refractory multiple myeloma. One year ago, Legend stunned the ASCO cancer convention with a very positive 94% response rate from a China trial of the CAR-T candidate. In December 2017, Janssen paid Legend a record $350 million upfront for a global partnership to develop the immunotherapy. Janssen and Legend plan to begin enrollment of the US trial in the second half of 2018. More details....

Stock Symbol: (HK: 1548)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.